Cardiorentis is a biopharmaceutical company, developing drug therapies for the treatment of acute heart failure and related cardiovascular diseases. The Company develops TRUE-AHF, an ularitide, which is an intravenous infusion treatment for acute heart failure; and SIRIUS I and II, a safety and efficacy study of an intravenous placebo controlled randomized infusion of ularitide in a prospective double–blind study in patients with symptomatic and decompensated chronic heart failures. Its disease-based technology platform includes protein biology to identify novel targets; design small molecule compounds and peptides for healthcare markets.